Yvette C. Terrie

Articles by Yvette C. Terrie

Yvette C. TerrieHR Breast Cancer | May 7, 2025

Real-world data reveal varying efficacy of CDK4/6 inhibitors in HR+/HER2- aBC, supporting personalized treatment choices.

Yvette C. TerrieTriple-Negative Breast Cancer | May 6, 2025

Darolutamide did not meet the clinical benefit endpoint in AR-positive TNBC, per findings from the phase II START trial.

Yvette C. TerrieTriple-Negative Breast Cancer | April 8, 2025

Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.

Yvette C. TerrieBreast Cancer News | April 6, 2025

Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.

Yvette C. TerrieHR Breast Cancer | April 4, 2025

Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.